TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06774625
Drug: LTG-001 Low Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LTG-001 Low Dose
Study: NCT06774625
Drug: LTG-001
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTG-001 is a Novel, Orally Bioavailable, Small Molecule NaV1.8 Inhibitor
Study: NCT05101096
Drug: Sacituzumab Govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously (IV)
Study: NCT05423717
Drug: Daridorexant 10 mg
Normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant will be taken orally, once daily in the evening during the treatment period.
Study: NCT05423717
Drug: Daridorexant 25 mg
Normalized name: daridorexant 25 MG
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant will be taken orally, once daily in the evening during the treatment period.
Study: NCT05423717
Drug: Daridorexant 50 mg
Normalized name: daridorexant 50 MG
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant will be taken orally, once daily in the evening during the treatment period.
Study: NCT06339788
Drug: Teneligliptin
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Single does administration of Teneligliptin and Empagliflozin High
Study: NCT06339788
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single does administration of Teneligliptin and Empagliflozin High
Study: NCT06655272
Drug: Bacterial Lysate
Normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration p.o. for 10 days per month for 3 months, two consecutive cycles.
Study: NCT04091386
Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)
Normalized name: damoctocog alfa pegol
DrugBank: Damoctocog alfa pegol (DB14700)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention is given as part of routine medical practice
Study: NCT06768905
Drug: CAR-T cell
Normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T cell therapy
Study: NCT06790706
Drug: DOMVANALIMAB + ZIMBERELIMAB
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with intravenous Domvanalimab at flat dose of 1200 mg + intravenous Zimberelimab at flat dose of 360 mg, administered every 3 weeks (Q3W, one cycle = 3 weeks).
Study: NCT06790706
Drug: DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with intravenous Domvanalimab at flat doses of 1600 mg + intravenous Zimberelimab at flat dose of 480 mg, administered every 4 weeks (Q4W), together with an induction treatment of intravenous FOLFOX-4 (Oxaliplatin 85 mg/m2 IV, L-folinic acid 200 mg/m2 IV, and fluorouracil 400 mg/m2 IV bolus on Day 1, fluorouracil 2400 mg/m2 IV continuous infusion over 46-48 hours starting on Day 1) given every 2 weeks, for 4 months (one cycle = 4 weeks).
Study: NCT06120283
Drug: BGB-43395
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned doses administered orally.
Study: NCT06120283
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard dose administered via intramuscular injection.
Study: NCT06120283
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dose administered orally as a tablet.
Study: NCT06642545
Drug: Disitamab Vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks
Study: NCT06642545
Drug: RC148
Normalized name: Romosozumab
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg/kg, intravenous infusion, once every 2 weeks
Study: NCT06642545
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg,intravenous infusion, once every 3 weeks
Study: NCT06719544
Drug: lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06259929
Drug: Abemaciclib 150 MG + Giredestrant 30 MG
Normalized name: abemaciclib 150 MG
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery
Study: NCT06287944
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06287944
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06287944
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given sirolimus
Study: NCT06287944
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given tacrolimus
Study: NCT06300463
Drug: Botensilimab
Normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg IV Q6W
Study: NCT06300463
Drug: Balstilimab
Normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg IV Q3W
Study: NCT06037980
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ◦ Gemcitabine 800 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
Study: NCT06037980
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ◦ Nab-paclitaxel 100 mg/mq, day 1 and 8 of 21-day cycles, for 3 cycles
Study: NCT06037980
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ◦ Cisplatin 25 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
Study: NCT05843786
Drug: Interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous administration of Interferon gamma during 5 days
Study: NCT05270525
Drug: Ensifentrine
Normalized name: Ensifentrine
DrugBank: Ensifentrine (DB16157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensifentrine twice daily administered with jet nebulizer for 8 weeks
Study: NCT04539366
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06449222
Drug: BNT327 Dose Level 1 (DL1)
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT06449222
Drug: BNT327 Dose Level 1 (DL2)
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06449222
Drug: Nab-placlitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT06449222
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT06449222
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT06449222
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT06449222
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT06449222
Drug: BNT327 Equivalent Q3W Dose
Normalized name: olopatadine
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06800651
Drug: JMKX003142 will be administered orally
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: JMKX003142 will be administered orally
Study: NCT06724926
Drug: Azeliragon
Normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azeliragon is orally administered. Patients start Azeliragon 7 days before CSI and take their last dose 7 days post-CSI.~The first 6 patients will start at Dose Level 1 \[DL1\] (Loading dose for 7 days: 30 mg twice daily; Concurrent/adjuvant dose: 20 mg once daily).~If 1 or fewer of 6 patients develop dose-limiting toxicity (DLT) then the recommended dose will be DL1. If at least 2 of 6 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -1 \[DL-1\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 10mg once daily).~If 1 or fewer out of 6 patients at DL-1 develop DLT, then the recommended dose will be DL-1. If at least 2 of 6 at DL-1 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -2 \[DL-2\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 5mg once daily).~At the recommended dose, an additional 14 patients will be enrolled for the Dose Expansion portion.
Study: NCT06755086
Drug: 18-FDG
Normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Study: NCT06540144
Drug: rozanolixizumab
Normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rozanolixizumab solution for injection
Study: NCT05406713
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg intravenously
Study: NCT06795906
Drug: AZD8630
Normalized name: AZD8630
DrugBank: AZD8630 (DB19397)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8630 will be administered via dry powder inhalation (DPI).
Study: NCT05507970
Drug: MMV367 (Fasted 440mg)
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose dispersed in sterile water fasted.
Study: NCT05514353
Drug: PBI-100 Topical Cream
Normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBI-100 Topical Cream in 1 of 3 dose levels
Study: NCT04781374
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
Study: NCT05599412
Drug: Lorviqua
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05613413
Drug: Cabozantinib 40 MG
Normalized name: cabozantinib 40 MG
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib is taken my mouth
Study: NCT05613413
Drug: Pembrolizumab 200mg
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is given intravenously
Study: NCT05613413
Drug: Pembrolizumab 400mg
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is given intravenously
Study: NCT04843904
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet, taken by mouth
Study: NCT04843904
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as an infusion into the vein (intravenous, IV).
Study: NCT04843904
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as an infusion into the vein (intravenous, IV).
Study: NCT06655246
Drug: ziftomenib
Normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: menin inhibitor
Study: NCT06655246
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: kinase inhibitor
Study: NCT04645160
Drug: Tivozanib
Normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tivozanib taken daily for Days 1-21 continuously (of each 28-day cycle) followed with 7 days off medication (except for patients in DL-1, with dosing every other day of the 28-day cycle). Phase I: The starting dose (DL1) is 0.89 mg taken once a day continuously for Days 1-21 with 1 week off medication (except for those patients assigned to DL-1, where tivozanib should be taken every other day, around 48 hours apart in 28-day cycle). Patients may escalate to 1.34 mg taken once a day (DL2) continuously for Days 1-21 with 1 week off medication for their second cycle if there are no dose-limiting toxicities. Phase II: Tivozanib dose level will be at the recommended Phase II dose (RP2D) established in Phase I.
Study: NCT05623488
Drug: huCART-meso cells
Normalized name: zeaxanthin, meso-
DrugBank: Zeaxanthin (DB11176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains
Study: NCT06705478
Drug: Pramipexole ER
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets self-administered orally
Study: NCT06705478
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets self-administered orally
Study: NCT06723080
Drug: VC005 low dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: VC005 low dose group repeat administration
Study: NCT06723080
Drug: VC005 high dose group
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 high dose group repeat administration
Study: NCT06070857
Drug: LV232
Normalized name: Levonorgestrel 232 mcg
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
Study: NCT06575686
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04578444
Drug: Zanidatamab
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04731558
Drug: enoxaparin or tinzaparin or dalteparin
Normalized name: Medicated Pad or Tape
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
Study: NCT06754163
Drug: Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Wegovy (semaglutide) will be provided as an induction dose of 0.25 mg, titrated up every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, will be given, with a maintenance dose of 2.4 mg or to the maximum tolerated dose.~To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to a maintenance dose of 2.4 mg once weekly. The semaglutide injection will be administered once weekly on the same day of the week throughout the study period. Injections will be administered in the thigh, abdomen or upper arm at any time of the day. As part of the multi-disciplinary approach taken in the STEP trials of Wegovy, patients willl be encouraged to~* Increase their physical activity~* Reduce their daily calorie intake~* Record their physical activity and dietary intake on their Food/Activity/Sleep (FAS) Diary Sheets A secondary goal is to achieve sustained improvements in participants' activity levels and awareness of a healthy diet.
Study: NCT06205550
Drug: Flecainide
Normalized name: Flecainide
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide monotherapy
Study: NCT06095570
Drug: Ciprofol
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For induction of anesthesia, an experimental dose of ciprofol was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
Study: NCT06095570
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For induction of anesthesia, an experimental dose of remimazolam was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
Study: NCT05426434
Drug: Dihydroartemisinin-Piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP (D-Artepp) will be supplied by Fosun Pharma, China. DP will consist of three 40mg/320mg) tablets given once a day for three consecutive days
Study: NCT05426434
Drug: Sulfadoxine pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.
Study: NCT06429176
Drug: SPL84
Normalized name: SPL84-23-1
DrugBank: SPL84-23-1 (DB18575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL84 solution for nebulization
Study: NCT06725017
Drug: Live SK08 powder
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK08 is an investigational live biotherapeutic product containing a nontoxigenic B. fragilis(NTBF) strain as an active ingredient.
Study: NCT05986318
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets
Study: NCT05986318
Drug: Dexamethasone Placebo
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Matching placebo for dexamethasone tablets
Study: NCT04882917
Drug: M4076
Normalized name: Metformin hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: M4076 was administered orally.
Study: NCT05950464
Drug: BET Bromodomain Inhibitor ZEN-3694
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05950464
Drug: Tuvusertib
Normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06735300
Drug: Nirmatrelvir/Ritonavir (Paxlovid)
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After providing the potential benefits and associated risks of antiviral treatment with Paxlovid, patients made well-informed decisions about whether or not to receive Paxlovid (300/100 mg nirmatrelvir/ritonavir, Pfizer Inc., New York, NY, USA) twice daily for 5 days.
Study: NCT05501600
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
Study: NCT06192615
Drug: Intravenous Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg)
Study: NCT06192615
Drug: Sublingual Dexmedetomidine
Normalized name: dexmedetomidine Sublingual Product
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual dexmedetomidine (120 μg)
Study: NCT06704698
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thoracic paravertebral block with liposomal bupivacaine.
Study: NCT06704698
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural block with plane bupivacaine.
Study: NCT06792695
Drug: Volrustomig
Normalized name: Volrustomig
DrugBank: Volrustomig (DB18893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volrustomig will be administered as intravenous (IV) infusion.
Study: NCT06792695
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered as IV infusion.
Study: NCT06677190
Drug: Belzutifan
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A Hypoxia-Inducible Factor-2 alpha inhibitor, 40 mg immediate-release tablet, taken orally per protocol.
Study: NCT06786637
Drug: Nociceptin Receptor Antagonist (LY-2940094)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist LY-2940094. Peak concentrations are achieved 2-4 hours post-administration.
Study: NCT06793683
Drug: Bladder chemodenervation (Botox)
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BoNT-A (Botox) 200 U will be injected into the detrusor (bladder wall muscle).
Study: NCT05747794
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel will be given as standard of care (chemotherapy)
Study: NCT04729322
Drug: Fecal Microbiota Transplantation Capsule
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04729322
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04729322
Drug: Neomycin
Normalized name: Neomycin
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO